Home | Publications | Diseases | Cancer place holder
place holder place holder

Cancer

Top 7 Cancer Indications

Therapeutic & Competitive Insights

Publication Date   January 2007
Publisher   Bioseeker
Product Type   Report
Pages   750
ISBN Number   not applicable
Product Code   BSK142
Ask a question about this product?

Price £4,715.00

approximately: $8,810 | €5,980

Summary


With our 750 page report entitled "Top 7 Cancer Indications - Therapeutic & Competitive Insights" we present one of the largest reports published evaluating therapeutic and competitive insights in the anti-cancer arena. The report is structured according to the top 7 cancer indications: Breast cancer, Colon/colorectal cancer, Leukemia, Lung cancer, Lymphoma, Melanoma, and Prostate cancer.

No other report will provide a likewise structure and analysis. The report not only provides a close to complete structure of each cancer indication field, it as well describes the progress of hundreds of drugs in development. Information on most company related activities are included. More than 250 companies are involved in developing new drugs within the top seven cancer indications.

In the report BioSeeker does not only describe and analyze the latest years of progress but as we well provide an insight and framework to understand the complex field of cancer therapeutics. The report provides one of the most comprehensive coverage of the R&D trends to set the future marketplace. BioSeeker presents both an overview and a detailed description on the progress of key drugs in Phase II and III development, together with general descriptions on drugs and targets. In total we have selected more than 360 drug candidates to analyze. Among these drugs we clearly see substantial progress while others have failed. There will be a more intense competition in this market and current treatments will be changed for the benefit of more innovative therapies.

Scope of this report

Progress analysis of Top 7 Cancer Indications, including players, drugs, clinical progress and pitfalls

  • Breast Cancer
  • Colon/colorectal cancer
  • Leukemia
  • Lung cancer
  • Lymphoma
  • Melanoma
  • Prostate Cancer

The report includes:

  • 250 drug developing companies
  • 360 candidate drugs
  • More than 160 Tables, 200 Boxes and 600 high quality references

Key reasons to read this report:

  • Understand the clinical and strategic challenges to the commercialization of drugs within the top 7 cancer indications
  • Assess opportunities and risks for the continued development of drugs in seven major cancer indications
  • Adopt knowledge from this analysis to drive strategic planning decisions in oncology drug development

Content


  • 1 Executive Summary
  • 2 Table Of Contents
    • 2.1 List Boxes
    • 2.2 List Of Figures
    • 2.3 List Tables
  • 3 Methodology
  • 4 Lung Cancer
    • 4.1 Introduction
      • 4.1.1 Disease Definition
      • 4.1.2 Etiology & Pathophysiology
      • 4.1.3 Prognosis
      • 4.1.4 Epidemiology
    • 4.2 Current Treatment Strategies
      • 4.2.1 Treatment Guide Lines
    • 4.3 Progress In Current Treatment Strategies
      • 4.3.1 Improvements adding microtubule inhibitor
      • 4.3.2 Improvement of disease related symptoms in elderly patients
      • 4.3.3 Toxicity profile favored
      • 4.3.4 A new formula
      • 4.3.5 Monotherapy?
      • 4.3.6 Failed to demonstrate a survival advantage
      • 4.3.7 Reduction in mortality risk
    • 4.4 Key Drug Strategies In Lung Cancer
      • 4.4.1 Therapeutic Type, Targets & Mechanisms
    • 4.5 Competitive Landscape In Drug Development: The Late Stage Pipeline
      • 4.5.1 Grade 4 adverse events
      • 4.5.2 No new remarks
      • 4.5.3 No significant effect on overall survival
      • 4.5.4 Bristol Myers Squibb entered into an agreement
      • 4.5.5 Many uncertainties remain
      • 4.5.6 Development terminated
      • 4.5.7 Continuing Enrollment
      • 4.5.8 Apoptotic inducer
      • 4.5.9 Fully-human monoclonal antibody
      • 4.5.10 Eagerly awaiting data
      • 4.5.11 Mutations and response
      • 4.5.12 Statistically and clinically significant survival advantage
      • 4.5.13 Anti-idiotypic monoclonal antibody
      • 4.5.14 Shift in the development focus
      • 4.5.15 Sensitizer
      • 4.5.16 Treatment in earlier-stage cancer could be more effective
      • 4.5.17 Discontinued radiosensitizer
      • 4.5.18 Improvement in chemoradiotherapy
      • 4.5.19 Progress on HDAC inhibitor
      • 4.5.20 Progress Analysis Carboxyamidotriazole
      • 4.5.21 Chemotherapy nave subjects
    • 4.6 Progress Profiles On Approved Drugs
      • 4.6.1 Docetaxel
      • 4.6.2 Vinorelbine
      • 4.6.3 Gemcitabine
      • 4.6.4 Paclitaxel
      • 4.6.5 Pemetrexed
      • 4.6.6 Gefitinib
      • 4.6.7 Erlotinib
  • 5 Colon Cancer
    • 5.1 Introduction
      • 5.1.1 Epidemiology
      • 5.1.2 Disease Definition
      • 5.1.3 Prognosis for Colorectal Cancer by Stage
    • 5.2 Current Treatment Strategies
      • 5.2.1 Treatment Guide Lines
    • 5.3 Progress In Current Treatment Strategies
      • 5.3.1 A 50% Increase in Sales!
      • 5.3.2 Topoisomerase inhibitor in First-line and Second-line Treatment
      • 5.3.3 Fast Way to Approval
      • 5.3.4 A Significant Reduction in the Risk of Death
      • 5.3.5 Mice and Men
      • 5.3.6 The Very Base
    • 5.4 Key Drug Strategies In Crc
      • 5.4.1 Therapeutic Type, Targets & Mechanisms
      • 5.4.2 An Answer to Drug Resistance
      • 5.4.3 Novel Therapies at the Gate
      • 5.4.4 Tumor Vascularization & Antivascular Agents
      • 5.4.5 Anti-angiogenesis: Therapeutic Strategies
      • 5.4.6 Single Agent Therapy: Poorly Active in Advanced Tumors
      • 5.4.7 Synergistic Effects with Cytotoxic Therapies
      • 5.4.8 Vascular Targeting Agents
      • 5.4.9 Vaccines
      • 5.4.10 Tumor antigens
      • 5.4.11 The Cell Vaccines Strategy
      • 5.4.12 Potent antigen presenting cells
      • 5.4.13 Emerging strategies
      • 5.4.14 Better-characterized antigens
    • 5.5 Competitive Landscape In Crc Drug Development
      • 5.5.1 We are in the Lead
      • 5.5.2 Amgen
      • 5.5.3 Novartis and Schering
      • 5.5.4 OSI, Genentech, Hoffmann La Roche & Pfizer
      • 5.5.5 Sanofi-Aventis
    • 5.6 Current Crc Drug Development
      • 5.6.1 Chemotherapy and Cytotoxic Drugs - A strategy reborn
      • 5.6.2 Progress Analysis: CoFactor
      • 5.6.3 Progress Analysis: Trabectedin (ET-743)
      • 5.6.4 Progress Analysis: Pemetrexed
      • 5.6.5 Progress Analysis: TS-1
      • 5.6.6 Progress Analysis: Edotecarin
      • 5.6.7 Progress Analysis: Aroplatin
      • 5.6.8 Progress Analysis: Ixabepilone
      • 5.6.9 EGF-R Inhibition and Other Signal Transduction Inhibitors
      • 5.6.10 Progress Analysis: Panitumumab
      • 5.6.11 Progress Analysis: Erlotinib (Tarceva)
      • 5.6.12 Progress Analysis: Gefitinib (Iressa)
      • 5.6.13 Progress Analysis: Pelitinib
      • 5.6.14 Progress Analysis: Sorafenib
      • 5.6.15 Signal Transduction Inhibitors in CRC
      • 5.6.16 Progress Analysis: BIO-117
      • 5.6.17 Progress Analysis: PD 0325901
      • 5.6.18 Antiangiogenetic- A team of players
      • 5.6.19 Progress Analysis: Vatalanib
      • 5.6.20 Progress Analysis: Thalidomide
      • 5.6.21 Progress Analysis: AMG 706
      • 5.6.22 Progress Analysis: Combretastatin A4 prodrug
      • 5.6.23 Progress Analysis: MBT 0206
      • 5.6.24 Progress Analysis: MEDI 522
      • 5.6.25 Progress Analysis: Tetrathiomolybdate
      • 5.6.26 Progress Analysis: WX-UK1
      • 5.6.27 COX-2 Inhibitors - What will become of us?
      • 5.6.28 Progress Analysis: P 54
      • 5.6.29 Progress Analysis: CV-247
      • 5.6.30 Apoptosis: An approach with a future
      • 5.6.31 Progress Analysis: HGS-ETR1
      • 5.6.32 Progress Analysis: APLIDIN
      • 5.6.33 Progress Analysis: VELCADE
      • 5.6.34 Progress Analysis: TELCYTA
      • 5.6.35 Progress Analysis EPO 906
      • 5.6.36 Progress Analysis: BIO-145
      • 5.6.37 Progress Analysis: Genasense
      • 5.6.38 Progress Analysis: Rexin-G
      • 5.6.39 Progress Analysis: Indisulam
      • 5.6.40 Progress Analysis: Seliciclib
      • 5.6.41 Progress Analysis: SYMADEX
    • 5.7 Necrotic Cell Death Inducers
      • 5.7.1 Progress Analysis: RAV12
      • 5.7.2 Progress Analysis: Cantuzumab mertansine
      • 5.7.3 Progress Analysis: HuC242-DM4
      • 5.7.4 Progress Analysis: COTARA
    • 5.8 Vaccines: A High Threshold To Success
      • 5.8.1 Cell Vaccine
      • 5.8.2 Progress Analysis: OncoVAX
      • 5.8.3 Progress Analysis CANVAXIN
      • 5.8.4 Progress analysis Collidem
      • 5.8.5 Progress Analysis Dendricell
      • 5.8.6 Progress Analysis: Neuvenge
      • 5.8.7 Progress Analysis: Onyvax-CR
      • 5.8.8 Progress Analysis: Ras-VAX
      • 5.8.9 Vaccine: Direct Immunization with Protein and peptides
      • 5.8.10 Progress Analysis Avicine
      • 5.8.11 Progress Analysis: Oncophage
      • 5.8.12 Progress Analysis EP 2101
      • 5.8.13 Progress Analysis: MSI vaccine
      • 5.8.14 Progress Analysis: Corixa's MUC-1 vaccine
      • 5.8.15 Progress Analysis: GV1002
      • 5.8.16 Anti-idiotype Monoclonal Antibodies
      • 5.8.17 Progress Analysis: CeaVac
      • 5.8.18 Progress Analysis: Onyvax-105
      • 5.8.19 DNA and Virally Encoded Vaccines
      • 5.8.20 Progress Analysis: TroVax
      • 5.8.21 Progress Analysis: ALVAC-CEA-B7.1
      • 5.8.22 Progress Analysis CEA-TRICOM
      • 5.8.23 Progress Analysis IR 705
      • 5.8.24 Progress analysis HYB-2055
      • 5.8.25 Passive Immunotherapy and Conjugated Antibodies
      • 5.8.26 Progress Analysis: IGN 101
      • 5.8.27 Progress Analysis: CEA-Cide
      • 5.8.28 Progress Analysis: LMB 9
      • 5.8.29 Progress Analysis: XR 303
      • 5.8.30 Progress Analysis ING-1
    • 5.9 Immuno-Modulators
      • 5.9.1 Progress Analysis: Dacogen
      • 5.9.2 Progress Analysis: GCAN-101
      • 5.9.3 Progress Analysis: ZYC300
      • 5.9.4 Progress Analysis: Clofarabine
    • 5.10 Oncolytic Virotherapy In Crc - A Team Of Four
      • 5.10.1 Progress Analysis: OncoVEX
      • 5.10.2 Progress Analysis: Oncolytic HSV
  • 6 Prostate Cancer
    • 6.1 Introduction
      • 6.1.1 Disease Definitions
      • 6.1.2 Etiology & Pathophysiology
      • 6.1.3 Epidemiology
      • 6.1.4 Prognosis
    • 6.2 Current Treatment Strategies
      • 6.2.1 Localized Disease
      • 6.2.2 Locally Advanced Prostate Cancer
      • 6.2.3 Metastatic Prostate Cancer
      • 6.2.4 Hormone-Sensitive Metastatic Prostate Cancer
      • 6.2.5 Hormone-Refractory or Recurrent Metastatic Prostate Cancer
    • 6.3 Progress In Current Treatment Strategies
      • 6.3.1 Long-Term Follow-up Data not yet Been Published
      • 6.3.2 Significant Reduced Risk of Distant Metastases
      • 6.3.3 Adverse Events
      • 6.3.4 No Difference in Overall Survival
      • 6.3.5 Cross-over Design an Optimal Option?
      • 6.3.6 Death due to Liver Failure
      • 6.3.7 Survival Benefit
      • 6.3.8 Subdermal Implant
      • 6.3.9 No FDA Approval
      • 6.3.10 No Improvement in 5-year Disease-Free Survival
      • 6.3.11 Effective Secondary Hormonal Therapy?
      • 6.3.12 Synery in Combination
    • 6.4 Key Therapeutic Strategies For Future Therapies
      • 6.4.1 Therapeutic Type, Targets & Mechanisms
    • 6.5 Competitive Landscape In Drug Development: The Late Stage Pipeline
      • 6.5.1 Reduced Prostate Cancer Risk
      • 6.5.2 High Activity in Metastatic AIPC Patients
      • 6.5.3 Absence of Severe Toxicities
      • 6.5.4 Waiting for Data
      • 6.5.5 Probability of Regulatory Approval?
      • 6.5.6 Co-development and License Agreement
      • 6.5.7 Improves Predicted Survival?
      • 6.5.8 Slow Progress & Development Partners
      • 6.5.9 Exclusive License Agreement
    • 6.6 Current Drug Development: The Early Stage Pipeline
      • 6.6.1 New Data?
      • 6.6.2 Terminated Study
      • 6.6.3 More Than 50% PSA decline
      • 6.6.4 Safety and Tolerability
      • 6.6.5 Terminated?
      • 6.6.6 Marker of Drug Effect
      • 6.6.7 Preliminary Results for a Tyrosine Kinase Inhibitor
      • 6.6.8 No Activity in Monotherapy
      • 6.6.9 Dramatic Disappearance of Bone Metastatic Lesions
      • 6.6.10 PSA Response - Anthracycline
  • 7 Breast Cancer
    • 7.1 Introduction
      • 7.1.1 Clinical Practice Guidelines
      • 7.1.2 Drugs approved by FDA
    • 7.2 Progress In Current Treatment Strategies
      • 7.2.1 A Hormone Therapeutic Losing Ground
      • 7.2.2 Top Three Aromatase Inhibitors
      • 7.2.3 Estrogen receptor downregulator
      • 7.2.4 Side effects & resistance
    • 7.3 Competitive Landscape In Drug Development: The Late Stage Pipeline
      • 7.3.1 First in New Class of Protein-Bound Particle Drugs
      • 7.3.2 High Efficacy and Reduced Cardiac Toxicity
      • 7.3.3 A chemopotentiator
      • 7.3.4 Microtubule-stabilizing agents
      • 7.3.5 A Protein kinase inhibitor in Phase III
      • 7.3.6 A bifunctional alkylating agent
      • 7.3.7 Breast Cancer Trials That Did Not Meet Primary Endpoints
    • 7.4 Current Drug Development: The Early Stage Pipeline
      • 7.4.1 Keeping a low Profile
      • 7.4.2 Protein Kinase Inhibitors a Future Treatment or Not?
      • 7.4.3 Alimta
      • 7.4.4 A Platinum Drug With Less Toxicity
      • 7.4.5 A Proteasome Inhibitor on Track
      • 7.4.6 Antisense: An Option for Breast Cancer or Not?
      • 7.4.7 Two farnesyl transferase inhibitor making progress
    • 7.5 Appendix B Near Term "breast Cancer" Progress
      • 7.5.1 Progress profile Abraxane
      • 7.5.2 Progress Profile Alimta
      • 7.5.3 Progress Profile Arimidex
      • 7.5.4 Progress Profile Aromasin
      • 7.5.5 Progress Profile Avastin
      • 7.5.6 Progress Profile BMS-217380-01
      • 7.5.7 Progress Profile BMS-247550
      • 7.5.8 Progress Profile CAELYX
      • 7.5.9 Progress Profile CCI-779
      • 7.5.10 Progress Profile Faslodex
      • 7.5.11 Progress Profile Femara
      • 7.5.12 Progress Profile Fenretinide
      • 7.5.13 Progress Profile Gleevec
      • 7.5.14 Progress Profile GTI-2040
      • 7.5.15 Progress Profile Herceptin
      • 7.5.16 Progress Profile Iressa
      • 7.5.17 Progress Profile ISIS-2503
      • 7.5.18 Progress Profile Lapatinib
      • 7.5.19 Progress Profile Nolvadex
      • 7.5.20 Progress Profile Sarasar
      • 7.5.21 Progress Profile SDX-105
      • 7.5.22 Progress Profile Tarceva
      • 7.5.23 Progress Profile Theratope
      • 7.5.24 Progress Profile Velcade
      • 7.5.25 Progress Profile Zarnestra
      • 7.5.26 Progress Profile Zoladex
      • 7.5.27 Progress Profile ZD0473
  • 8 Melanomas
    • 8.1 Introduction
      • 8.1.1 Etiology and Pathophysiology
    • 8.2 Current Treatment Strategies
    • 8.3 Progress In Current Treatment Strategies
    • 8.4 Cytotoxic Drugs
      • 8.4.1 Dacarbazine
      • 8.4.2 Cisplatin
      • 8.4.3 Carboplatin
      • 8.4.4 Carmustine
      • 8.4.5 Melphalan
      • 8.4.6 Paclitaxel
      • 8.4.7 Tamoxifen
      • 8.4.8 Temozolomide
      • 8.4.9 Vinblastine/Vinorelbine
    • 8.5 Biological Treatments
      • 8.5.1 Virulizin
      • 8.5.2 Melacine
      • 8.5.3 Alfanative (Multiferon)
      • 8.5.4 Proleukin or (Macrolin)
      • 8.5.5 Ceplene Maxamine
    • 8.6 Competitive Lanscape In Drug Development: The Late Stage Pipeline
      • 8.6.1 Phase I & II R&D Collaborations in Melanoma: Oxxon
      • 8.6.2 Roche links Schering-Plough and Chugai Clusters Together - What Will the Outcome Be?
      • 8.6.3 GlaxoSmithKline Brings Wyeth, Hayashibara, Cytokinetics and Coley Pharmaceuticals Together
      • 8.6.4 GlaxoSmithKline and Sanofi-Aventis have a Joint Middle Man
      • 8.6.5 R&D Collaboration Trends in Melanoma Projects
    • 8.7 Key Therapy Strategies
      • 8.7.1 Therapeutic Type, Targets & Mechanisms
    • 8.8 Current Drug Development: The Early Stage Pipeline
      • 8.8.1 Vaccines: Active Immunotherapy a Benefit or Not?
      • 8.8.2 Vaccine: Direct Immunization with Tumor Antigens
      • 8.8.3 Progress Analysis: Oncophage
      • 8.8.4 Progress Analysis: GMK
      • 8.8.5 Progress Analysis: NOVOVAC-M1
      • 8.8.6 Progress Analyses: SB 249553
      • 8.8.7 Progress Analysis: MJV 101
      • 8.8.8 Progress Analysis: A Russian Melanoma Vaccine
      • 8.8.9 Progress Analysis: GV 1001
      • 8.8.10 Progress Analyses: Elea Vaccine
      • 8.8.11 Progress Analysis: NY-ESO-1 ISCOMS
      • 8.8.12 Progress Analysis: F 50040
      • 8.8.13 Progress Analysis: Transvax
      • 8.8.14 Vaccines: Is the Development of Cell Therapy Stalling?
      • 8.8.15 Progress Analysis: Canvaxin
      • 8.8.16 Progress Analysis: Dexosome
      • 8.8.17 Progress Analysis: M-VAX ORGINAL
      • 8.8.18 Progress Analysis: OncoVax
      • 8.8.19 Progress Analysis: Uvidem
      • 8.8.20 DNA Vaccine
      • 8.8.21 Progress Analysis: Alvac-Mage1/Mage3
      • 8.8.22 Progress Analysis: Oxxon Vaccine
      • 8.8.23 Progress Analysis: Therion's Melanoma Vaccine
      • 8.8.24 Progress Analysis: ImmunoVex trimelan
      • 8.8.25 Progress Analysis: OncoVEXGM-CSF
      • 8.8.26 Progress Analysis: GVAX
      • 8.8.27 Progress Analysis: Gp100 + MART-1
      • 8.8.28 Progress Analysis: MAGE-3-TK OR M3TK
      • 8.8.29 Optimism for New Vaccine Adjuvants
      • 8.8.30 Progress Analysis: Enhanzyn
      • 8.8.31 Progress Analysis: QS-21
      • 8.8.32 Progress Analysis: Zadaxin
      • 8.8.33 Progress Analysis: Mobista
      • 8.8.34 Progress Analysis: ProMune
      • 8.8.35 Progress Analysis: Talabostat
      • 8.8.36 Immunostimulants: The Push in Passive Immunotherapy
      • 8.8.37 Immuno-Biologicals: The Work Horse
      • 8.8.38 Progress Analysis: MDX-010
      • 8.8.39 Progress Analysis: Peginterferon alfa-2b
      • 8.8.40 Progress Analysis: Iboctadekin
      • 8.8.41 Progress Analysis: BAY 504798
      • 8.8.42 Progression Analysis: EMD 273063
      • 8.8.43 Progress Analysis: Urocidin
      • 8.8.44 Progress Analysis: CP-675206
      • 8.8.45 Immunostimulation by Gene Therapy
      • 8.8.46 Progress Analysis: ALLOVECTIN-7
      • 8.8.47 Inovio Biomedical Corporation and Lee Moffitt Cancer Center Make a Joint move in Melanoma Gene therapy
      • 8.8.48 Progress Analysis: TG 1041
      • 8.8.49 One Small Molecular Drug Candidate
      • 8.8.50 Progress Analysis: Lenalidomide
      • 8.8.51 Antiangiogenesis- The Major Research Focus for the Next Decade?
      • 8.8.52 Progress Analysis: Sorafenib
      • 8.8.53 Progress Analysis: Vitaxin
      • 8.8.54 Progress Analysis: Avastin
      • 8.8.55 Progress Analysis: Endostatin
      • 8.8.56 Progress Analysis: PI 88
      • 8.8.57 Apoptosis Inducers: Moving into Market
      • 8.8.58 Progress Analysis: Genasense
      • 8.8.59 Progress Analysis: Didemnin B
      • 8.8.60 Progress Analysis: INGN 241
      • 8.8.61 Progress Analysis: KOS 953
      • 8.8.62 Small Molecules Inhibiting Cell Growth Faces Difficulties
      • 8.8.63 Progress Analysis: Temozolomide
      • 8.8.64 Progress Analysis: Pivanex
      • 8.8.65 Progress Analysis: Karenitecin
      • 8.8.66 Progress Analysis: Lomeguatrib
      • 8.8.67 Progress Analysis: PD 0325901
      • 8.8.68 Progress Analysis: SB 715992
      • 8.8.69 Progress Analysis: INO 1001
      • 8.8.70 Progress Analysis: CP 4055
      • 8.8.71 Other Biological Drugs
      • 8.8.72 Progress Analysis: AP 12009
      • 8.8.73 Progress Analysis: Ecromeximab
      • 8.8.74 Progress Analysis: ILX 651
      • 8.8.75 Progress Analysis: Kahalalide F
      • 8.8.76 Progress Analysis: ABX MA1
  • 9 The Lymphomas
    • 9.1 Introduction
      • 9.1.1 Disease Definition
      • 9.1.2 Etiology & Pathophysiology
      • 9.1.3 Epidemiology
      • 9.1.4 Prognosis
      • 9.1.5 Hodgkin's Disease
        • 9.1.5.1 Cellular Classification
        • 9.1.5.2 Stage Information
      • 9.1.6 Non-Hodgkin
        • 9.1.6.1 Cellular Classification
        • 9.1.6.2 Stage Information
    • 9.2 Current Treatment Strategies
      • 9.2.1 Hodgkin's Disease
      • 9.2.2 Radiation Therapy
      • 9.2.3 Chemotherapy
      • 9.2.4 Transplantation
      • 9.2.5 Treatment Option Overview
      • 9.2.6 Non-Hodgkin's Lymphoma
      • 9.2.7 Radiation Therapy
      • 9.2.8 Chemotherapy
      • 9.2.9 Immunotherapy